In addition to T1D, MDA5 inhibitors may also be useful in the treatment of other autoimmune diseases where exacerbated MDA5 responses may play a role, such as SLE (71, 72), MS (69, 70), or RA (73, 74). Here, IFIH1 is linked to myeloid sarcoma.